FLT201, a novel liver-directed AAV gene therapy candidate for Gaucher disease type 1. Molecular Therapy. 2025; 33(8):3789-3807.
Intrinsic link between PGRN and Gba1 D409V mutation dosage in potentiating Gaucher disease. Human Molecular Genetics. 2024; 33(20):1771-1788.
iPSC-derived neural precursor cells engineering GBA1 recovers acid β-glucosidase deficiency and diminishes α-synuclein and neuropathology. Molecular Therapy: Methods & Clinical Development. 2023; 29:185-201.
Earlier-onset, more severe neurodegeneration in PGRN KO mice with a decreased dose of D409V Gba1. Molecular Genetics and Metabolism. 2023; 138(2):107207.
A brain penetrant progranulin-derived biologic protects against neuronopathic Gaucher disease. Molecular Genetics and Metabolism. 2023; 138(2):107367.
PGRN deficiency exacerbates, whereas a brain penetrant PGRN derivative protects, GBA1 mutation-associated pathologies and diseases. Proceedings of the National Academy of Sciences of the United States of America. 2023; 120(1):e2210442120.
Treatment of a genetic brain disease by CNS-wide microglia replacement. Science Translational Medicine. 2022; 14(636):eabl9945.
Analysis of the Biomarkers for Neurodegenerative Diseases in Aged Progranulin Deficient Mice. International Journal of Molecular Sciences. 2022; 23(2).
Editorial: Neuronopathic lysosomal storage diseases - specific neuronal characteristics and therapeutic approaches. Frontiers in Molecular Neuroscience. 2022; 15:1078804.
Progranulin associates with Rab2 and is involved in autophagosome-lysosome fusion in Gaucher disease. Journal of Molecular Medicine. 2021; 99(11):1639-1654.
Substrate Reduction Therapy Reverses Mitochondrial, mTOR, and Autophagy Alterations in a Cell Model of Gaucher Disease. Cells. 2021; 10(9).